Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection

Katherine A. Scilla, Dan P. Zandberg, Søren M. Bentzen, Candace Mainor, Jonathon Heath, Olga B. Ioffe, Ashley L. Cellini, Martin J. Edelman, David J. Riedel, Josephine Feliciano

Research output: Contribution to journalArticle

Abstract

Objective: Co-signaling molecules PD-L1, B7-H3, and PD-1 play a key role in cancer immunology. There are limited but emerging data on expression of these molecules in HIV-infected lung cancer patients. Materials and Methods: We reviewed archived lung cancer tissue samples from HIV-infected cases (n = 13) and HIV-uninfected controls (n = 13) from 2001-2015. Cases and controls were matched by histology and stage. Immunostained tumor sections were analyzed for percent of tumor cells expressing PD-L1 and B7-H3, and percent of tumor infiltrating immune cells (TII) expressing PD-1 and PD-L1. Positive expression was defined as >5%. Statistical analysis was performed using the non-parametric Mann-Whitney test and the chi-square test. Results: PD-L1 expression on tumor cells was positive in 23% of cases and 46% of controls. B7-H3 expression on tumor cells was positive in 92% of cases and 69% of controls. PD-1 expression on TII was positive in 69% of cases and 54% of controls. PD-L1 expression on TII was positive in 31% of cases and 69% of controls. B7-H3 percent expression on tumor cells was significantly higher in cases vs. controls (median 90% vs 20%, p = 0.005), but there were no significant differences in percent expression of PD-L1 on tumor cells, PD-1 on TII or PD-L1 on TII. Conclusion: HIV-infected lung cancer patients had significantly higher B7-H3 tumor expression compared to HIV-uninfected controls, with similar rates of tumor PD-L1 expression, as well as PD-1 and PD-L1 expression on TII. These results support inclusion of HIV-infected lung cancer patients in future immunotherapy trials.

Original languageEnglish (US)
Pages (from-to)87-90
Number of pages4
JournalLung Cancer
Volume123
DOIs
StatePublished - Sep 1 2018

Fingerprint

Virus Diseases
Case-Control Studies
Lung Neoplasms
HIV
Neoplasms
Chi-Square Distribution
Allergy and Immunology
Immunotherapy
Histology

Keywords

  • B7-H3
  • Human immunodeficiency virus
  • Lung cancer
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. / Scilla, Katherine A.; Zandberg, Dan P.; Bentzen, Søren M.; Mainor, Candace; Heath, Jonathon; Ioffe, Olga B.; Cellini, Ashley L.; Edelman, Martin J.; Riedel, David J.; Feliciano, Josephine.

In: Lung Cancer, Vol. 123, 01.09.2018, p. 87-90.

Research output: Contribution to journalArticle

Scilla, KA, Zandberg, DP, Bentzen, SM, Mainor, C, Heath, J, Ioffe, OB, Cellini, AL, Edelman, MJ, Riedel, DJ & Feliciano, J 2018, 'Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection', Lung Cancer, vol. 123, pp. 87-90. https://doi.org/10.1016/j.lungcan.2018.06.028
Scilla, Katherine A. ; Zandberg, Dan P. ; Bentzen, Søren M. ; Mainor, Candace ; Heath, Jonathon ; Ioffe, Olga B. ; Cellini, Ashley L. ; Edelman, Martin J. ; Riedel, David J. ; Feliciano, Josephine. / Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. In: Lung Cancer. 2018 ; Vol. 123. pp. 87-90.
@article{775ac50938dc4004ad7941ed9a839ffb,
title = "Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection",
abstract = "Objective: Co-signaling molecules PD-L1, B7-H3, and PD-1 play a key role in cancer immunology. There are limited but emerging data on expression of these molecules in HIV-infected lung cancer patients. Materials and Methods: We reviewed archived lung cancer tissue samples from HIV-infected cases (n = 13) and HIV-uninfected controls (n = 13) from 2001-2015. Cases and controls were matched by histology and stage. Immunostained tumor sections were analyzed for percent of tumor cells expressing PD-L1 and B7-H3, and percent of tumor infiltrating immune cells (TII) expressing PD-1 and PD-L1. Positive expression was defined as >5{\%}. Statistical analysis was performed using the non-parametric Mann-Whitney test and the chi-square test. Results: PD-L1 expression on tumor cells was positive in 23{\%} of cases and 46{\%} of controls. B7-H3 expression on tumor cells was positive in 92{\%} of cases and 69{\%} of controls. PD-1 expression on TII was positive in 69{\%} of cases and 54{\%} of controls. PD-L1 expression on TII was positive in 31{\%} of cases and 69{\%} of controls. B7-H3 percent expression on tumor cells was significantly higher in cases vs. controls (median 90{\%} vs 20{\%}, p = 0.005), but there were no significant differences in percent expression of PD-L1 on tumor cells, PD-1 on TII or PD-L1 on TII. Conclusion: HIV-infected lung cancer patients had significantly higher B7-H3 tumor expression compared to HIV-uninfected controls, with similar rates of tumor PD-L1 expression, as well as PD-1 and PD-L1 expression on TII. These results support inclusion of HIV-infected lung cancer patients in future immunotherapy trials.",
keywords = "B7-H3, Human immunodeficiency virus, Lung cancer, PD-1, PD-L1",
author = "Scilla, {Katherine A.} and Zandberg, {Dan P.} and Bentzen, {S{\o}ren M.} and Candace Mainor and Jonathon Heath and Ioffe, {Olga B.} and Cellini, {Ashley L.} and Edelman, {Martin J.} and Riedel, {David J.} and Josephine Feliciano",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2018.06.028",
language = "English (US)",
volume = "123",
pages = "87--90",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection

AU - Scilla, Katherine A.

AU - Zandberg, Dan P.

AU - Bentzen, Søren M.

AU - Mainor, Candace

AU - Heath, Jonathon

AU - Ioffe, Olga B.

AU - Cellini, Ashley L.

AU - Edelman, Martin J.

AU - Riedel, David J.

AU - Feliciano, Josephine

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objective: Co-signaling molecules PD-L1, B7-H3, and PD-1 play a key role in cancer immunology. There are limited but emerging data on expression of these molecules in HIV-infected lung cancer patients. Materials and Methods: We reviewed archived lung cancer tissue samples from HIV-infected cases (n = 13) and HIV-uninfected controls (n = 13) from 2001-2015. Cases and controls were matched by histology and stage. Immunostained tumor sections were analyzed for percent of tumor cells expressing PD-L1 and B7-H3, and percent of tumor infiltrating immune cells (TII) expressing PD-1 and PD-L1. Positive expression was defined as >5%. Statistical analysis was performed using the non-parametric Mann-Whitney test and the chi-square test. Results: PD-L1 expression on tumor cells was positive in 23% of cases and 46% of controls. B7-H3 expression on tumor cells was positive in 92% of cases and 69% of controls. PD-1 expression on TII was positive in 69% of cases and 54% of controls. PD-L1 expression on TII was positive in 31% of cases and 69% of controls. B7-H3 percent expression on tumor cells was significantly higher in cases vs. controls (median 90% vs 20%, p = 0.005), but there were no significant differences in percent expression of PD-L1 on tumor cells, PD-1 on TII or PD-L1 on TII. Conclusion: HIV-infected lung cancer patients had significantly higher B7-H3 tumor expression compared to HIV-uninfected controls, with similar rates of tumor PD-L1 expression, as well as PD-1 and PD-L1 expression on TII. These results support inclusion of HIV-infected lung cancer patients in future immunotherapy trials.

AB - Objective: Co-signaling molecules PD-L1, B7-H3, and PD-1 play a key role in cancer immunology. There are limited but emerging data on expression of these molecules in HIV-infected lung cancer patients. Materials and Methods: We reviewed archived lung cancer tissue samples from HIV-infected cases (n = 13) and HIV-uninfected controls (n = 13) from 2001-2015. Cases and controls were matched by histology and stage. Immunostained tumor sections were analyzed for percent of tumor cells expressing PD-L1 and B7-H3, and percent of tumor infiltrating immune cells (TII) expressing PD-1 and PD-L1. Positive expression was defined as >5%. Statistical analysis was performed using the non-parametric Mann-Whitney test and the chi-square test. Results: PD-L1 expression on tumor cells was positive in 23% of cases and 46% of controls. B7-H3 expression on tumor cells was positive in 92% of cases and 69% of controls. PD-1 expression on TII was positive in 69% of cases and 54% of controls. PD-L1 expression on TII was positive in 31% of cases and 69% of controls. B7-H3 percent expression on tumor cells was significantly higher in cases vs. controls (median 90% vs 20%, p = 0.005), but there were no significant differences in percent expression of PD-L1 on tumor cells, PD-1 on TII or PD-L1 on TII. Conclusion: HIV-infected lung cancer patients had significantly higher B7-H3 tumor expression compared to HIV-uninfected controls, with similar rates of tumor PD-L1 expression, as well as PD-1 and PD-L1 expression on TII. These results support inclusion of HIV-infected lung cancer patients in future immunotherapy trials.

KW - B7-H3

KW - Human immunodeficiency virus

KW - Lung cancer

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85049804715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049804715&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.06.028

DO - 10.1016/j.lungcan.2018.06.028

M3 - Article

C2 - 30089601

AN - SCOPUS:85049804715

VL - 123

SP - 87

EP - 90

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -